Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

asparaginase Erwinia chrysanthemi (Rx)Brand and Other Names:Erwinaze

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, powder for reconstitution

  • 10,000 IU/vial
more...

Acute Lymphoblastic Leukemia

Asparagine specific enzyme indicated as part of a multiagent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase

Substitution for pegaspargase: 25,000 IU/m² IM/IV 3 times/week (Monday/Wednesday/Friday) for 6 doses (for each planned dose of pegaspargase)

Substitution for native E. coli asparaginase: 25,000 IU/m² IM/IV for each scheduled dose of native E. coli asparaginase

Dosage Forms & Strengths

injection, powder for reconstitution

  • 10,000 IU/vial
more...

Acute Lymphoblastic Leukemia

Asparagine specific enzyme indicated as part of a multiagent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase

Use in children: A single-arm, multi-center, open-label, safety and clinical pharmacology trial of 58 patients was conducted during the clinical trials; median age was 10 years (2-18 years)

Substitution for pegaspargase: 25,000 IU/m² IM/IV 3 times/week (Monday/Wednesday/Friday) for 6 doses (for each planned dose of pegaspargase)

Substitution for native E. coli asparaginase: 25,000 IU/m² IM/IV for each scheduled dose of native E. coli asparaginase

Next

Adverse Effects

>10%

Hypersensitivity reactions, including anaphylaxis (17%)

1-10%

Hypersensitivity, grades 3/4 (5%)

Glucose intolerance (5%)

Pancreatitis (4%)

Fever (3%)

Coagulation abnormalities (3%)

Thrombosis (2%)

Hyperglycemia (2%)

Headache (1%)

Hyperbilirubinemia (1%)

Abnormal transaminases (>1%)

Coagulation abnormalities including thrombosis and hemorrhage (>1%)

Nausea (>1%)

Vomiting (>1%)

Postmarketing reports

Abdominal pain/discomfort

Diarrhea

Local reactions

Previous
Next

Warnings

Contraindications

History of serious hypersensitivity reactions to asparaginase Erwinia chrysanthemi, including anaphylaxis

History of serious pancreatitis with prior L-asparaginase therapy

History of serious thrombosis with prior L-asparaginase therapy

History of serious hemorrhagic events with prior L-asparaginase therapy

Cautions

Serious hypersensitivity reactions, including anaphylaxis have occurred; administer in setting with resuscitation equipment; discontinue drug if hypersensitivity reaction occurs

Glucose intolerance reported and in some cases, may be irreversible; monitor serum glucose levels at baseline and periodically during treatment

Serious thrombotic events, including sagittal sinus thrombosis reported with both E. coli and Erwinia-derived L-asparaginase therapy; coagulation proteins were decreased in the majority of patients after a 2-week course (eg, fibrinogen, protein C activity, protein S activity, and anti-thrombin III); discontinue for a thrombotic or hemorrhagic event until symptoms resolve; after resolution, treatment may resume

Pancreatitis

  • Pancreatitis reported during clinical trials
  • Discontinue drug for severe or hemorrhagic pancreatitis manifested by abdominal pain >72 hr and amylase elevation 2.0 x ULN or more
  • Mild pancreatitis: hold drug until signs and symptoms subside, and amylase levels return to normal; after resolution, treatment may resume
Previous
Next

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Unknown whether distributed in breast milk

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Mechanism of Action

Catalyzes deamidation of asparagine to aspartic acid and ammonia, thereby reducing circulating levels of asparagine

The mechanism of action is thought to be based on the inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity

The lack of asparagine synthetase activity results in cytotoxicity specific for leukemic cells that depend on an exogenous source of the amino acid asparagine for their protein metabolism and survival

Pharmacokinetics

Serum trough concentration: 0.1 IU/mL or greater at 48-72 hr

Serum activity levels 0.4 IU/mL or greater shown in 80% at 48 hr and in 38% at 72 hr

Half-life: 16 hr (IM)

Previous
Next

Administration

IM Preparation

Visually inspect the powder for foreign particulate matter and discoloration prior to reconstitution; do use vial if present

Reconstitute vial contents by slowly injecting 1 or 2 mL of preservative free sterile sodium chloride (0.9%) injection against the inner vial wall

Do not forcefully inject solution for reconstitution directly onto or into the powder

When reconstituted with 1 mL the resultant concentration is 10,000 IU/mL

When reconstituted with 2 mL the resultant concentration is 5,000 IU/mL

Dissolve contents by gentle mixing or swirling; do not shake or invert vial When reconstituted, solution should be a clear and colorless

Do not use the reconstituted solution if any visible particles or protein aggregates are present

Calculate the dose needed and the volume needed to obtain the calculated dose

Withdraw the volume containing the calculated dose from the vial into a polypropylene syringe within 15 minutes of reconstitution

Administer within 4 hr or discard

IM Administration

Limit volume of single injection site to 2 mL; if volume of dose exceeds 2 mL, use multiple injection sites

If a partial vial is used, do not save or reuse the unused drug for later administration; discard unused portions

IV Preparation

Slowly inject the reconstituted asparaginase into an IV infusion bag containing 100 mL of 0.9%NaCl acclimatized to room temperature

Do not shake or squeeze IV bag

If partial vial is used, do not save or reuse the unused drug for later administration; discard unused portions

IV Administration

Infuse asparaginase in 100 mL of normal saline over 1-2 hr

Do not infuse other drugs through same IV line while administering asparaginase

Storage

Store unused or unopened vials and cartons at 36-46°F (2-8°C) and protect from light

Do not freeze or refrigerate reconstituted solution

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.